Gloria Melanie 4

What Happened

• Gloria Melanie, Chief Operating Officer of Immunovant, sold 3,238 shares on Feb 25, 2026 in three open-market disposals to cover tax withholding tied to vested RSUs. Reported amounts: 1,437 shares @ $26.98 ($38,770), 859 shares @ $28.16 ($24,189), and 942 shares @ $28.90 ($27,224), for total proceeds of about $90,183.
• This was a sale to satisfy tax obligations following the vesting/settlement of RSUs and was mandated by the issuer’s “sell to cover” election — a routine, non‑discretionary transaction rather than a voluntary decision to liquidate holdings.

Key Details

• Transaction date: 2026-02-25; Form 4 filed 2026-02-27 (timely filing).
• Reported prices are weighted averages; the underlying trades occurred within ranges: $26.66–$27.60, $27.67–$28.61, and $28.70–$29.13 (per footnotes).
• Total shares sold: 3,238; total proceeds reported ≈ $90,183.
• Sale related to RSUs originally granted 11/18/2024; 6,872 RSUs vested on 2/18/2026 (footnote F1). The sale was to cover tax withholding (footnote F1); F2–F4 explain price ranges/weighted averages.
• Shares owned after the transaction are not specified in the provided excerpt.

Context

• This was a tax-withholding (sell-to-cover) sale tied to RSU vesting, which is common and generally not read as a personal bearish signal. The filing indicates multiple executions aggregated into weighted-average prices; the Reporting Person can provide detailed per-trade prices on request.